Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. - Wikidata - awgldk - TriplyDB

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

http://www.wikidata.org/entity/Q37481863

about

Recurrent Glioblastoma: Where we stand Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma Medical management of brain tumors and the sequelae of treatment.Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Angiogenic inhibition in high-grade gliomas: past, present and future.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.Experimental approaches for the treatment of malignant gliomas.Impact of imaging measurements on response assessment in glioblastoma clinical trials Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches Antiangiogenic therapy for glioblastoma: current status and future prospects.Bevacizumab for the treatment of recurrent glioblastoma.Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme The future of high-grade glioma: Where we are and where are we going.Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanism Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741 Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.Carboplatin and bevacizumab for recurrent malignant glioma.Standards of care for treatment of recurrent glioblastoma--are we there yet?Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Bevacizumab for the treatment of glioblastoma.

P2860

Q26765042-5DF8AEDE-F578-4EE8-A9A3-925EEBFE64B0 Q26767169-4145EC6B-28F9-4998-9317-5B268B8C6DAA Q26992174-14D9A8B0-0296-4983-A2D5-3EA57834FF13 Q27001560-C4AB752D-22D3-4FA8-9DFD-82C5FC190416 Q30455596-5E0DEC06-90F0-48FE-8BD1-49B71E5449D7 Q30616602-68AF908F-5430-4EA5-BBD6-DC7339764A56 Q30737224-84012E15-5FAD-4D05-A802-002DD888E448 Q33392078-8939C32D-8A2F-43FC-840D-8F1BF8DD6AB9 Q33397569-1517CF1E-FB52-42DE-B8C9-AA1603D8C417 Q33419628-FEF2C0C6-8CF5-42B7-98DA-DBD4AF5F9A74 Q33421314-1B4C192E-2457-47C3-9478-958820EE5362 Q33616632-0BF6DDC2-5AAD-46F3-9B89-BC28FD41BB11 Q33864058-9BC0F80A-AC37-4C98-9612-560D4B250CE2 Q34062017-E9C7A6BF-0060-4CC9-9343-689F6B53E8E5 Q34127138-74AA45FD-3E55-4769-8563-AF520CD6FC6D Q34331328-F32D66FC-DD7A-4356-AA11-0A7303D2F076 Q34480689-96ADEFAC-8585-448B-A03D-C26D7B146F43 Q34515465-D5950439-1D80-41B2-8F43-47B71850AFFF Q34523319-3C7E4021-4799-40C1-88C9-515927B5390A Q34982777-BEA3C9CE-D433-46EB-91AF-F7C408692180 Q35008766-9AF8EA9F-4A9E-4002-B827-BA80F8D15ECE Q35027024-73667EBF-8EE0-4E3B-A983-7E264FCE6FBD Q35114090-B9CC051D-0AC0-4E3A-8CDB-F482186C243B Q35172814-7C425915-AD0B-49E6-8D71-26242893FAAF Q35362682-5F3F4A4F-50B7-46D7-8CFF-C58D8922AEB9 Q35580650-DE376B17-7F96-4C89-860F-7BF9F74B3690 Q35584926-92FCBEEE-40A1-46F8-ACB6-37CCAFA6F06B Q35621495-42718F6A-58AE-4D91-AFEA-E83884ED0CDB Q35895174-99649F58-891A-4ECD-8F6E-097BEDA3AFD9 Q36007805-336A6B10-3554-45EE-A8FA-598B799FF2D1 Q36103026-5402EF7E-F5F8-4184-9247-1AD749F40DD6 Q36112002-2B1AD1DC-3371-4082-BD77-8384F22D4D7B Q36172732-0CC4DB85-203A-4255-BECE-4975A85945BF Q36318341-3774D8B9-6780-44AB-A0B2-35A175E5B923 Q36367414-8820C4D7-4B5B-478B-A035-D0518F17D79D Q36385285-860E4379-3D5F-4711-B12E-93584EE4BB3B Q36403389-26B075A2-151B-4070-BD39-BFFB7A628E73 Q36500401-70A4843B-9B9B-4F97-A0DB-C3BEB57C177D Q36849213-8D0E823F-DA34-47F2-99FD-69CB102F3590 Q36929502-093A0175-A0E8-4D26-B56A-022193301CA5

P2860

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

http://www.wikidata.org/entity/Q37481863

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@en

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@nl

type

label

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@en

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@nl

prefLabel

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@en

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@nl

P1433

Q37481863-1D47DF85-2A10-4BA3-8B7A-2934DF755D16

P1476

Q37481863-10B1B2F4-DE51-4B81-823B-E0E0737A6AED

P2093

Q37481863-06EB06AF-2C4E-4534-BB0A-A90E908A3F08

Q37481863-0792F2D4-A874-461C-8EA9-43301761C744

Q37481863-132587AD-5791-4B84-99AE-A0B296B878FD

Q37481863-29B678B8-E5CB-4DF0-B0B8-0136CDF50347

Q37481863-3AB23EC4-AA6D-40F8-A26C-0680FE3F8C8E

Q37481863-87E7193C-031A-48F2-A068-61ECD420800C

Q37481863-95832DA0-60A3-448F-9459-5336B9DA41AB

Q37481863-9A3B7EE0-2028-4130-BCF9-2DBA00CA1A37

Q37481863-A2F15547-27A2-4F98-A645-E34EA99BE509

Q37481863-BCD4A481-DA7B-42F5-A070-64BF839E5818

P2860

Q37481863-056D5DAB-3FFD-493A-A553-F520DB39CF67

Q37481863-130957D2-0F74-4878-B6E5-D1D0CC90801F

Q37481863-15955A17-98D4-426B-9DA6-7BBC1B0BFE60

Q37481863-1DEE9C41-4EAA-436C-BC44-DA9B362A8134

Q37481863-20993ECB-2F03-4DCB-952B-8EAB145616A0

Q37481863-20C43026-9743-43B8-ACDC-DC8292190918

Q37481863-29AD561C-F85E-49B1-B125-471EEE5E16F9

Q37481863-2B85B32F-111A-4CE9-9445-062F101B077A

Q37481863-2E159F8C-6718-4AB5-A83A-BE1FB417325A

Q37481863-2F571004-48CD-471C-BE9E-B956D9AE0A14

P2888

Q37481863-F22021B4-EA05-4C0F-9EB0-C4F7D44DB671

P304

Q37481863-ABDCF18E-52C8-4593-B321-7CFEAE2DEE7A

P31

Q37481863-85A3D3D2-CC68-43CE-B4CB-CC2389BEDB53

P356

Q37481863-B82D330A-8610-4581-9979-86701C101295

P407

Q37481863-EF4435E8-2E2C-4BB2-94B9-EC4F25A8A032

P433

Q37481863-C7F5F3B4-440B-4D2E-A8A8-C69DFD55195F

P478

Q37481863-070B045B-4B33-46BB-A930-C6135AAA5727

P50

Q37481863-710C95DB-B34A-499F-A2A6-2E44ECCD5438

Q37481863-F2EBF08A-87B9-419D-9634-070D7C2D314B

P577

Q37481863-657C9053-DCC5-4825-83FF-367343B3EF87

P5875

Q37481863-06C57347-B955-4543-AC71-411726CB6CB8

P6179

Q37481863-6018549A-A9B9-4060-A0BD-C60DB8FCA6CE

P698

Q37481863-5089F681-4587-4807-9546-FCA14B137D58

P921

Q37481863-90B72C55-8A90-4699-BF5E-099D3316C083

Q37481863-AFFC2FA1-3720-45A1-B78D-43666A2E0CC7

P932

Q37481863-6249D673-ACDC-4AF9-BD0D-2A363CAE7067

P356

P1433

British Journal of Cancer

P1476

Metronomic chemotherapy with d ...... nant glioma: a phase II study.

@en

P2093

A Desjardins

http://www.w3.org/2001/XMLSchema#string

A H Friedman

http://www.w3.org/2001/XMLSchema#string

D A Reardon

http://www.w3.org/2001/XMLSchema#string

J E Herndon

http://www.w3.org/2001/XMLSchema#string

J E Marcello

http://www.w3.org/2001/XMLSchema#string

J H Sampson

http://www.w3.org/2001/XMLSchema#string

J J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

J Norfleet

http://www.w3.org/2001/XMLSchema#string

R E McLendon

http://www.w3.org/2001/XMLSchema#string

S Gururangan

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Malignant gliomas in adults

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Capillary rarefaction and abnormal cardiovascular reactivity in hypertension.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide.

P2888

P304

1986-1994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605412

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

P577

2009-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38096583

http://www.w3.org/2001/XMLSchema#string

P6179

1008522472

http://www.w3.org/2001/XMLSchema#string

P698

19920819

http://www.w3.org/2001/XMLSchema#string

P921

P932

2795427

http://www.w3.org/2001/XMLSchema#string